NasdaqCM - Nasdaq Real Time Price USD

enGene Holdings Inc. (ENGN)

15.50

+0.78

(+5.30%)

At close: April 26 at 4:00 PM EDT

15.20

-0.30

(-1.94%)

After hours: April 26 at 5:16 PM EDT

/C O R R E C T I O N -- enGene Inc./

enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Raj Pruthi MD MHA FACS has joined the Company as SVP, Urologic Oncology and Clinical Development, reporting to enGene's Chief Medical Officer, Dr. Richard Bryce. In this role, Dr. Pruthi's responsibilities will include sup

CNW Group 17 days ago

ENGN
+5.30%
ENGNW
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the first quarter ended January 31, 2024.

PR Newswire last month

ENGN
+5.30%
ENGNW
enGene To Present at the Leerink Partners Global Biopharma Conference

enGene Holdings Inc. (Nasdaq: ENGN) or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Jason Hanson, Chief Executive Officer, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on March 13, 2024, at 8:40 a.m. ET.

CNW Group last month

ENGN
+5.30%
ENGNW
enGene Announces Oversubscribed $200 Million Private Placement Financing

enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that it has agreed to sell 20 million of its common shares at a price per share of $10.00, representing a 31% premium over the closing price on February 13, 2024. The financing is expected to close on February 16, 2024, subject to customary closing cond

PR Newswire 2 months ago

ENGN
+5.30%
ENGNW
enGene Announces Leadership Succession Plan

enGene Holdings Inc. (Nasdaq: ENGN) ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that due to personal family and health reasons, Jason Hanson intends to resign from his role as Chief Executive Officer and a member of the Board of Directors upon the appointment of a successor CEO. The Board of Directors has initiated a search for his

PR Newswire 2 months ago

ENGN
+5.30%
ENGNW
enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Lee Giguere as Chief Legal Officer and Corporate Secretary.

CNW Group 2 months ago

ENGN
+5.30%
ENGNW
enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

enGene Holdings Inc. (Nasdaq: ENGN) (or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the fiscal year ended October 31, 2023 and provided a corporate update.

PR Newswire 2 months ago

ENGN
+5.30%
ENGNW
enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

enGene Holdings Inc. ("enGene," Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead EG-70 program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), announced today that it has entered into an amended USD $50 million loan agreement (the "Loan Agreement") with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). Under the Loan Agreement, which has a term of four years, $22.5 million has been advanced to enGene under a non-revolving term loan and,

CNW Group 4 months ago

ENGN
+5.30%
ENGNW

HTGC
enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors

enGene Holdings Inc. ("enGene," Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Lota S. Zoth, CPA, as a member of the Board of Directors and Audit Committee Chair.

CNW Group 4 months ago

ENGN
+5.30%
ENGNW
enGene Appoints Ryan Daws as Chief Financial Officer

enGene Holdings Inc. ("enGene,") (NASDAQ: ENGN) (NASDAQ: ENGNW), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment of Ryan Daws as Chief Financial Officer and Head of Business Development.

CNW Group 4 months ago

ENGN
+5.30%
Individual investors account for 39% of enGene Holdings Inc.'s (NASDAQ:ENGN) ownership, while private equity firms account for 37%

Key Insights Significant control over enGene Holdings by individual investors implies that the general public has more...

Simply Wall St. 5 months ago

ENGN
+5.30%
ENGNW
Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company

CAD$191 million gross proceeds from the transaction to support the advancement of the clinical program and pipeline expansionPivotal clinical trial for lead program EG-70 targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) currently ...

ACCESSWIRE 5 months ago

ENGN
+5.30%

Performance Overview

Return	ENGN	S&P 500
YTD	+67.93%	+6.92%
1-Year	+47.20%	+25.26%
3-Year	--	+12.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

enGene Holdings Inc. (ENGN)

/C O R R E C T I O N -- enGene Inc./

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

enGene To Present at the Leerink Partners Global Biopharma Conference

enGene Announces Oversubscribed $200 Million Private Placement Financing

enGene Announces Leadership Succession Plan

enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors

enGene Appoints Ryan Daws as Chief Financial Officer

Individual investors account for 39% of enGene Holdings Inc.'s (NASDAQ:ENGN) ownership, while private equity firms account for 37%

Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company

Performance Overview